Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Functional Analysis of Histone Methyltransferase G9a in B and T Lymphocytes

Lance R. Thomas, Hiroki Miyashita, Robin Milley Cobb, Steven Pierce, Makoto Tachibana, Elias Hobeika, Michael Reth, Yoichi Shinkai and Eugene M. Oltz
J Immunol July 1, 2008, 181 (1) 485-493; DOI: https://doi.org/10.4049/jimmunol.181.1.485
Lance R. Thomas
*Department of Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroki Miyashita
†Experimental Research Center for Infectious Diseases, Institute for Virus Research, Department of Molecular and Cellular Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Milley Cobb
*Department of Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Pierce
*Department of Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makoto Tachibana
†Experimental Research Center for Infectious Diseases, Institute for Virus Research, Department of Molecular and Cellular Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elias Hobeika
‡Faculty of Biology, University of Freiburg and Max-Planck Institute of Immunobiology, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Reth
‡Faculty of Biology, University of Freiburg and Max-Planck Institute of Immunobiology, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoichi Shinkai
†Experimental Research Center for Infectious Diseases, Institute for Virus Research, Department of Molecular and Cellular Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene M. Oltz
*Department of Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Lymphocyte development is controlled by dynamic repression and activation of gene expression. These developmental programs include the ordered, tissue-specific assembly of Ag receptor genes by V(D)J recombination. Changes in gene expression and the targeting of V(D)J recombination are largely controlled by patterns of epigenetic modifications imprinted on histones and DNA, which alter chromatin accessibility to nuclear factors. An important component of this epigenetic code is methylation of histone H3 at lysine 9 (H3K9me), which is catalyzed by histone methyltransferases and generally leads to gene repression. However, the function and genetic targets of H3K9 methyltransferases during lymphocyte development remain unknown. To elucidate the in vivo function of H3K9me, we generated mice lacking G9a, a major H3K9 histone methyltransferase, in lymphocytes. Surprisingly, lymphocyte development is unperturbed in G9a-deficient mice despite a significant loss of H3K9me2 in precursor B cells. G9a deficiency is manifest as modest defects in the proliferative capacity of mature B cells and their differentiation into plasma cells following stimulation with LPS and IL-4. Precursor lymphocytes from the mutant mice retain tissue- and stage-specific control over V(D)J recombination. However, G9a deficiency results in reduced usage of Igλ L chains and a corresponding inhibition of Igλ gene assembly in bone marrow precursors. These findings indicate that the H3K9me2 epigenetic mark affects a highly restricted set of processes during lymphocyte development and activation.

Adaptive immunity relies on a temporal reprogramming of gene expression to guide the development of lymphocytes, their activation by Ags, and clonal expansion of effector cells. During lymphocyte development, large cohorts of genes are either activated or repressed to ensure proper transition between two cell types. These genetic programs include the process of V(D)J recombination, which is responsible for the tissue- and stage-specific assembly of Ag receptor genes (1). Coordination of the lymphocyte transcriptional program and V(D)J recombination is regulated by cis-acting elements that, in turn, alter the accessibility of chromatin to nuclear factors. A primary mechanism by which cis-elements modulate chromatin accessibility is the covalent modification of its components, histones and DNA. The specific pattern of epigenetic modifications serves as a code to recruit proteins that alter chromatin accessibility to DNA-binding factors, including V(D)J recombinase and the transcription machinery (1, 2, 3).

An important component of the mammalian epigenome is modification of histone H3 lysine 9 (H3K9),3 which is targeted by histone acetyltransferases and histone deacetylases. In general, acetylation of H3K9 leads to high-affinity interactions with bromodomains in other histone acetyltransferases or nucleosome-remodeling complexes, which further augment chromatin accessibility and induce transcription (3, 4, 5). In contrast, H3K9 methylation at promoters inhibits gene expression via recruitment of proteins that impair chromatin accessibility (6). The extent of methylation at H3K9 varies between types of repressive chromatin. Mono- and dimethylated forms of H3K9 (H3K9me1 and -me2) generally are found in euchromatin, suggesting a role for these modifications in dynamic mechanisms of repression (7). In contrast, trimethylated H3K9 (H3K9me3) is found predominantly at pericentric heterochromatin (8).

H3K9 methylation is catalyzed by one of six known histone methyltransferases (HMT) in mammals, which all contain an enzymatic SET domain. These H3K9 HMTs are expressed ubiquitously but display distinct enzymatic activities and patterns of chromosomal localization. The G9a/GLP proteins form heteromeric complexes and catalyze H3K9me1 and H3K9me2 at euchromatin (9). Similarly, ESET is found in euchromatic regions and is proposed to catalyze the conversion of H3K9me2 to H3K9me3 (10, 11, 12). The H3K9 HMT called RIZ1 is inactivated in a variety of human tumors, but its function in the modification of endogenous chromatin remains unknown (13). The redundant enzymes Suv39h1 and -h2 catalyze H3K9me3 and associate with pericentric heterochromatin. The functional significance of each H3K9 HMT has been confirmed by mouse knockout studies. Dual deletion of Suv39h1/2 results in reduced viability, genomic instability, and the lack of H3K9me3 at pericentric heterochromatin (8). Knockouts of G9a or GLP result in early embryonic lethality and substantially reduced levels of H3K9me1 and -me2 at euchromatin (7, 9).

In addition to changes in lymphocyte gene expression, the crosstalk between cis-acting elements and epigenetic modifications plays a key role in tissue- and stage-specific control of V(D)J recombination. This gene assembly process creates critical checkpoints that guide lymphocyte development and generates a diverse repertoire of Ig and TCR genes (1, 14, 15). In brief, a pro-B cell initially targets the RAG-1/2 components of V(D)J recombinase to assemble variable (V), diversity (D), and joining (J) gene segments that are selected randomly from large arrays within the Ig heavy (IgH) chain locus (16). Formation of a productive IgH gene stimulates developmental progression to the pre-B cell stage and V→J recombination at IgL chain loci, which also proceeds in a stepwise manner (Igκ precedes Igλ). A similar genetic program is used during thymocyte development, in which pro-T cells initiate Dβ→Jβ rearrangement followed by Vβ→DβJβ assembly. On incorporation into a pre-TCR, TCRβ signals for differentiation into pre-T cells and activation of Vα→Jα rearrangement. The control mechanisms that direct V(D)J recombinase to specific clusters of gene segments rely on changes in chromatin accessibility (17). Indeed, the accessibility status of specific Ig and TCR gene segments correlates with their epigenetic modification. Similar to expressed genes, recombinationally active segments are hyperacetylated but hypomethylated at H3K9 (18, 19). Using model substrates, we recently established a cause-effect relationship between H3K9 methylation by G9a and repression of recombinase accessibility (20).

Despite these advances, little is known about the in vivo role of any H3K9 HMT in either V(D)J recombination or the gene expression programs that guide lymphocyte development. To address this issue, we generated mice that are devoid of G9a specifically in B or T cells. Mutant lymphocytes exhibit significantly reduced levels of H3K9me2 but not H3K9me3. Surprisingly, lymphocyte development is unperturbed by this whole-scale reduction of H3K9me2. B cell proliferation is modestly affected by G9a deficiency, but the humoral immune response to a T-dependent Ag is largely normal. Although tissue-specific control of V(D)J recombination remains intact, Igλ gene rearrangement is reduced in G9a-deficient pre-B cells. Together, these findings indicate that G9a is the major H3K9 dimethyltransferase in B cells; however, global defects in H3K9me2 affect a highly restricted set of processes in lymphocyte development and function.

Materials and Methods

G9a conditional knockout mice

Preparation of the G9acnd allele as well as mb1-Cre and Lck-Cre mice are published elsewhere (21, 22, 23). To generate mice with G9a-deficient B cells, we bred the G9acnd allele into the mb1-Cre background, which already had a G9aΔ allele, to produce mb1-Cre/G9acnd/Δ mice. The G9aΔ allele arose from spurious Cre-mediated deletion of G9acnd in the germ cells of an mb1-Cre/G9awt/cnd mouse. All animal studies have been reviewed and approved by the Vanderbilt Institutional Review Board.

Immunoblotting

Immunoblotting analyses of global histone modifications and G9a were performed as described (7).

PCR and chromatin immunoprecipitation (ChIP) assays

For recombination, DNA extracts were prepared from primary lymphocytes (1000 cells/μl) as outlined (24). Primers and probes to detect rearrangements have been described for VαJα (25), VγJγ (26), VδJδ (27), VHDHJH (24), VκJκ (28), Dβ1Jβ1 (20), and Vβ12 and Vβ14 (29). Vβ16: primer, GGACCCAAAGTCTTACAGATCCC; Dβ2Jβ2, CACGATGTAACATTGTGGGGACTG and TCAGATCCCCACCAACCATGAGTG; probe, CCTTCACCAAAGTAGAGCTGC. VλJλ: primer, ATGAATTCACTGGTCTAATAGGTGGTACCA, CTAGGACAGTCAGTTTGGTTCC, and CTAGGACAGTGACCTTGGTTCC; probes, TGCTGTACCATAGAGCACAGAAAT (all VλJλ), GGTGTTCGGTGGAGG (Vλ1Jλ1), and TATGTTTTCGGCGGT (Vλ2Jλ2). For transcription assays, total RNA was extracted from lymphocytes using Trizol (Invitrogen) and converted to cDNA as described (20). Assays for RT-PCR have been reported for JH (30); Jκ (31); Blimp-1 (32); IgG1 germline transcripts (33); Vλ1, Vλ2, Jλ1, Jλ2, and β-actin (28). Activation-induced deaminase (AID): primer, GTGCCACCTCCTGCTCACTGG and TTCATGTAGCCCTTCCCAGGC; probe, GTGGCTGAGTTTCTGAGATGG. IgJ, primers, ATGAAGACCCACCTGCTTCTCTGG and TTGCTCTGGGTGGCAGTAACAACC; probe, ATGTGTACCCGAGTTACC. ChIP assays on B cell precursors were performed as described previously (34). Primers for Dβ ChIPs have been reported (20). JH4 ChIP: primer, GCTCAGTCACCGTCTCCTCAGG and GCCTCCAAAGTCCCTATCCCATC; probe, GGCTGAGAGAAGTTGGG. Jκ ChIP, primers, CGTTCGGTGCTGGGACCAAGC and GCCACGTCAACTGATAATGAGCCCTCTCC; probe, GACCAAGCTGGAGCTGAAACG. Vλ1 ChIP: primers, CCCCTGCAAACAGATGAGAAATCC and GCCTGCTGCTGACCAATATTG; probe, GAAAAGAATAGACCTGGTT. Vλ2 ChIP: CTGGCTCCTGCAAACAGGTA and GCCTGCTGCTGACCAATATTG; probe, GAAAATAATAGACTTGGTT. Jλ1 ChIP: primers, GATCTTTCAGTGATGTCACCACC and GCACCTCAAGTCTTGGAGAGAAC; probe, GGTGTTCGGTGGAGG. All amplification products were analyzed by Southern blotting.

Flow cytometry

Abs for cell surface markers were purchased from BD Biosciences except anti-Igλ-PE (Upstate Biotechnologies). Flow cytometry was performed on a FACSCalibur (BD Biosciences) and analyzed using CellQuest software.

Cell purification

MACS was used to purify splenic (CD43−) or bone marrow (B220+) B cells following the manufacturer’s protocol (Miltenyi Biotec). Splenic T cells were isolated using a mouse T cell Negative Isolation Kit (Dynal Biotech). Isolation of pro- and pre-B cell populations was performed as described (30).

Cell proliferation assays

Purified lymphocytes were seeded in 96-well plates (106/ml) and cultured in RPMI supplemented with 10% FCS. Proliferation was induced in B cell cultures with anti-IgM (Jackson Immunoresearch Laboratories), LPS (Sigma), or anti-CD40 (BD Biosciences) and in T cells by precoating wells with anti-CD3 (2C11, 1 μg/ml). After 48 h (B cells) or 60 h (T cells), [3H]TdR was added to each well, cells were incubated for 12–18 h, and TdR incorporation was quantified using liquid scintillation counting.

Immunization

Eight-week-old mice were immunized by i.p. injection of keyhole limpet hemocyanin (KLH; Sigma-Aldrich) at a concentration of 100 μg/50 μl/mouse mixed 1:1 with CFA (Difco). Serum was collected preimmunization or 3 wk postinjection. Total or KLH-specific Ig levels were measured by ELISA (Southern Biotech) as described (35).

Ig class switching

CD43− spleen cells (5 × 105) were cultured for 6 days with 5 μg/ml LPS ± 5 ng/ml mouse IL-4 (Peprotech). IgG1 and IgE were detected by ELISA (Southern Biotech).

Results

Lymphocyte-specific inactivation of G9a

Germline inactivation of the gene encoding G9a leads to early embryonic lethality in mice, precluding studies of lymphocyte development (7). To circumvent this obstacle, we generated embryonic stem (ES) cells with a G9a allele containing loxP sites that flank exons 26 and 27 (G9acnd), which encode for its enzymatic SET domain (23). Expression of Cre recombinase in cells containing the G9acnd mutation deletes floxed exons and produces a functionally null G9a allele (G9aΔ; Ref. 23). The G9acnd allele was passed into the mouse germline as described (23).

To generate mice with G9a-deficient B cells, we bred G9acnd and mb1-Cre mice. The latter strain harbors a Cre expression cassette driven by the endogenous mb1 (Igα) promoter, which is expressed in early progenitor B cells (21). Southern blotting confirmed that G9acnd was efficiently converted to G9aΔ (>90%) in bone marrow and splenic B cells (B220+) from the mb1-Cre genetic background (Fig. 1⇓A). In contrast, non-B cells (B220−) retained the G9acnd configuration, confirming cell type-specific deletion by mb1-Cre. To generate T cell-specific G9a knockouts, we crossed G9acnd mice with lck-Cre-transgenic animals (22). Southern blot analysis of G9acnd/lck-Cre offspring confirmed T lineage-specific conversion to G9aΔ alleles (∼90%) in both thymus and peripheral lymphoid organs (data not shown). Western blot analysis of G9a protein expression revealed almost complete ablation of this HMT in B lineage cells from mb1-Cre crosses, whereas residual G9a was detected in thymocytes and resting T cells from lck-Cre crosses (Fig. 1⇓, B and C).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Generation of G9a conditional knockout mice. A, Generation of the G9aΔ allele in B cells. G9acnd mice were crossed with mb1-Cre animals and genomic DNA was isolated from thymus (T) or from the B220+ and B220− cell fractions of the spleen (SP) and bone marrow (BM) of mice with the indicated genotypes. Tissue DNA was digested with HindIII and analyzed by Southern blotting. Sizes of the G9acnd (4.6 kb) and G9aΔ (5.8 kb) alleles are indicated at the right. B, Loss of G9a protein and H3K9me2 in B cells. B220+ cells were purified from bone marrow or spleen of G9aΔ/Δ and G9acnd/Δ mice. A portion of splenic B cells was cultured for 2 days in LPS-containing medium. Protein lysates were probed on immunoblots with a G9a-specific Ab. Immunoblot analysis of H3K9me was performed on nuclear protein extracts. The blot was sequentially probed with Abs specific for H3K9me2 and H3K9me3 as well as total H3 protein. C, Protein extracts from indicated lck-Cre/G9acnd/cnd cells were analyzed by immunoblotting as described in B. Control samples from either heterozygous or G9a-deficient ES cells are included. Total histone H4 levels serve as a protein loading control.

Prior studies established that G9a deficiency in ES cells produces a dramatic and specific decrease in global H3K9me2 (7). To determine whether this functional phenotype is recapitulated in G9a-deficient lymphocytes, we purified these cells and immunoblotted protein extracts for H3K9 modifications. Global levels of H3K9me2 are significantly decreased in resting and LPS-stimulated B cells from mb1-Cre/G9acnd mice when compared with control cells (≤20%; Fig. 1⇑B and data not shown). As expected, levels of H3K9me3 are largely unaffected by G9a deletion (7). In contrast, only a modest reduction in global H3K9me2 is observed in T cells from lck-Cre/G9acnd mice (Fig. 1⇑C), which correlates with persistent G9a expression. Notwithstanding, these data indicate that G9a is the major H3K9 dimethyltransferase in lymphocytes.

G9a-deficient lymphocytes develop normally

Given the global nature of the H3K9me2 mark on chromatin, we reasoned that G9a would regulate important aspects of gene expression programs that guide lymphocyte development, activation, and differentiation. Initially, we examined lymphocyte development using flow cytometric analyses of cell surface markers. Surprisingly, G9a-deficient mice generate a normal complement of mature B cells in their bone marrow and spleen despite a substantial defect in global H3K9me2 (Fig. 2⇓A). Likewise, G9a deletion by lck-Cre does not significantly alter thymocyte development or generation of splenic T cells (Fig. 2⇓B). Thus, expression of G9a and consequential H3K9me2 are largely dispensable for proper development of effector B and T cells.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Lymphocyte development in G9a conditional knockout mice. A, Bone marrow or splenic cells from wild-type (G9acnd/Δ mb1-cre−) or mb1-Cre crosses with G9acnd/Δ mice were analyzed by flow cytometry. Bone marrow cells were stained with anti-CD43-biotin, streptavidin-FITC, and anti-B220-PE (top). Spleen cells were stained with anti-IgM-FITC and anti-B220-PE (bottom). All data were gated for live lymphocyte populations. Representative FACS plots from independent analyses of at least eight mice for each genotype are shown. The percentages for each cell population are shown. No reproducible differences were observed in total cell numbers for spleen or bone marrow (BM) samples from any of the genotypes. B, T cell development was examined in thymocytes (top) from lck-Cre/G9acnd/cnd and wild-type animals, which were stained with CD4-FITC and CD8-PE (top). CD3-FITC and B220-PE stains revealed normal levels of B and T cell populations in the spleen samples from G9a-deficient animals (bottom).

Lymphocyte proliferation and humoral immune response

To test whether G9a plays an important role in lymphocyte activation programs, B cells were purified from control or G9aΔ/Δ spleens and cultured with polyclonal agonists LPS or anti-IgM. As shown in Fig. 3⇓A, G9a-deficient B cells exhibit only a modest proliferation defect upon LPS stimulation. However, proliferation of G9aΔ/Δ B lymphocytes is inhibited ∼4-fold after BCR cross-linking with anti-IgM. Decreased proliferation does not result from enhanced cell death in the induced cultures as monitored by annexin V-7-aminoactinomycin D staining (apoptotic fraction: wild type 31 ± 17%, G9aΔ/Δ 36 ± 10% for LPS; wild type 53 ± 10%, G9aΔ/Δ 60 ± 8% for anti-IgM). Furthermore, these effects are agonist specific because mutant cells proliferate normally upon CD40 cross-linking (data not shown). No significant defects are observed in the proliferative capacity of G9a-deficient T cells upon treatment with anti-CD3 Abs (data not shown). These data indicate that G9a is required for optimal activation of B cells following engagement of their Ag receptor.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Proliferative defects and primary immune responses. A, Purified splenic B cells from G9aΔ/+ or G9aΔ/Δ mice were stimulated for 2 days with indicated amounts of LPS or anti-IgM. Proliferation was determined by [3H]TdR incorporation after an 18-h pulse. Experiments from two mice of each genotype are shown and are representative of at least 15 independent experiments using both G9aΔ/+ mb1-cre+ and G9acnd/Δ mb1-cre− mice as wild-type controls. B, Natural Ig levels. Serum was collected from six G9aΔ/+ or six G9aΔ/Δ littermates at 8 wk of age. Steady-state levels of total serum Ig or specific Ig isotypes were determined by ELISA assays. Relative values for total Ig, IgM, Igκ, and Igλ are shown. No significant differences were observed in any IgH isotype (data not shown). Bars represent mean values of Ig concentration for each genotype. C, ELISA for IgH isotypes. Purified splenic B cells were stimulated with 5 ng/ml LPS ± 5 ng/ml IL-4. After 6 days, culture media were collected, and ELISA was used to determine IgG1 and IgE titers. Data are representative of two independent experiments. D, RNA expression analysis for B cell activation genes. Total RNA was prepared from wild-type or G9a-deficient B cells stimulated for 3.5 days with LPS alone (5 μg/ml) or LPS with 5 ng/ml IL-4. RNA was reverse transcribed, and the resultant cDNA was subject to PCR assays specific for Blimp-1, IgJ, AID, germline IgG1 transcripts, or β-actin. Titrations represent 3-fold dilutions. E, Plasma cell formation. G9aΔ/Δ and control splenocytes were stimulated for 3.5 days in the presence of LPS and IL-4 as in D. The percentage of plasma cells in these cultures was determined by FACS using FITC-B220 and PE-CD138. The circled fractions highlight the plasma cell subset.

In addition to proliferation, the B cell activation program includes Ig isotype switching, affinity maturation, and terminal differentiation into Ig-secreting plasma cells. Isotype switching and affinity maturation require AID, whose expression is regulated by the transcription factor Blimp-1 (36). Importantly, Blimp-1 interacts with G9a to mediate gene-specific H3K9me2 and gene repression (37). To test whether these processes are perturbed upon G9a deletion, we measured steady-state levels of circulating Ig proteins. Steady-state levels of IgH isotypes in G9aΔ/Δ mice are normal (Fig. 3⇑B and data not shown); however, a 50% reduction in circulating Igλ is observed in the mutant animals. Similar results for IgH isotypes (unchanged) and Igλ (reduced) are obtained following immunization with the T-dependent Ag KLH in CFA (data not shown).

To more rigorously test whether G9a regulates class switch recombination (CSR), purified B cells from control and G9aΔ/Δ mice were cultured with the polyclonal agonist LPS for 6 days in the presence or absence of the TH2 cytokine IL-4. As shown in Fig. 3⇑C, G9aΔ/Δ cells undergo class switching, but produce significantly less IgG1 and IgE than their wild-type counterparts. RT-PCR indicates that AID expression is unaffected by G9a deletion (Fig. 3⇑D). Likewise, no differences are observed in germline transcription of the IgG1 locus, a prerequisite for its CSR (Fig. 3⇑D). In contrast, expression of two plasma cell markers, Blimp-1 and J chain (IgJ), are ∼3-fold lower in G9aΔ/Δ cells upon stimulation with LPS and IL-4 but not with LPS treatment alone (Fig. 3⇑D). Quantitative real-time PCR assays confirmed the reduction in Blimp-1 (3-fold) and IgJ mRNA expression (2.5-fold; data not shown). These findings suggest that G9a deficiency inhibits plasma cell differentiation, rather than CSR, leading to reduced secretion of IgG1 and IgE in LPS + IL-4 B cell cultures. Indeed, FACS indicated a 2-fold reduction of plasma cell differentiation in G9aΔ/Δ cultures after LPS+IL-4 stimulation for 3 days (Fig. 3⇑E). Again, the paucity of plasma cells in these cultures could not be attributed to enhanced cell death because annexinV-7-aminoactinomycin D staining reveals similar numbers of apoptotic cells for the wild-type and G9a-deficient genotypes (data not shown). Together, these data indicate a specific role for G9a in processing the cues that lead activated B cells into their terminal differentiation program under certain stimulatory conditions.

G9a is dispensable for tissue-specific control of V(D)J recombination

Prior studies established correlations between H3K9me and tissue- or stage-specific repression of recombinase accessibility (18, 19). Moreover, G9a-mediated methylation of H3K9 inhibits recombination of chromosomal substrates (20). Our finding that lymphocyte development is unaffected in G9a-deficient mice suggested that it is dispensable for most aspects of Ag receptor gene assembly. However, these cell-based assays are insufficient to probe whether G9a is required for tissue-specific repression of Ig loci in thymocytes or TCR loci in developing B cells.

To test whether repression of TCR gene assembly is compromised in G9a-deficient B cells, we measured products of V(D)J recombination in DNA from bone marrow or splenic B cells. As shown in Fig. 4⇓A, repression of TCRα and TCRβ recombination is maintained in B cells from G9a-deficient mice. Similarly, the loss of G9a fails to induce rearrangement of TCRγ or TCRδ loci in B cells. Analogous assays were used to probe for loss of tissue-specific Ig gene assembly in G9a-deficient T cells. These sensitive assays fail to detect IgH or IgL gene rearrangements above background levels from contaminating B cells in thymocytes from G9a-deficient mice (Fig. 4⇓B). Although we observed no gross thymocyte developmental defects in G9a-deficient mice (Fig. 2⇑B), it remained possible that cellular selection processes are masking potential rearrangement defects at the endogenous TCRβ locus. To test this possibility, we measured D-to-J rearrangements of Dβ1 and Dβ2 gene segments, which indicate that the initial stage of TCRβ assembly is unaffected by the loss of G9a (Fig. 4⇓B). Likewise, rearrangement of distal (Vβ16), medial (Vβ12), and proximal (Vβ14) Vβ gene segments to Dβ1 remains largely normal upon deletion of G9a (Fig. 4⇓B).

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Maintenance of tissue-specific V(D)J recombination in the absence of H3K9me2. A, TCR rearrangement assays in G9a-deficient B cells. DNA from purified B220+ cells, from bone marrow (BM) or spleen (SP), of two G9acnd/Δ or G9aΔ/Δ mice was subjected to PCR assays for Vα→Jα, Dβ→Jβ, Vγ→Jγ, or Vδ→Jδ coding joins. Samples from a RAG-deficient pro-B cell line (63-12) or thymocytes served as negative and positive controls, respectively. Total DNA content for each sample was measured using PCR for Cλ. The linearity of each assay was confirmed using 1/3 serial dilutions of unsorted G9acnd/Δ thymus DNA. B, Rearrangement of Ig and TCR genes in G9a-deficient T cells. Thymocyte DNA from two G9aΔ/+ or G9aΔ/Δ mice was subjected to PCR assays for the indicated IgH, IgL, and TCR rearrangements. DNA from B220+ bone marrow cells or thymocytes was used as a positive control, and the wedge indicates 1/3 dilutions of these samples. C, ChIP assays for H3K9 modifications of the TCRβ or IgH loci in G9a-deficient precursor B cells. Chromatin from wild-type and G9a-deficient pro-B or a mixture of predominantly pre-B cells was immunoprecipitated with Abs specific for H3K9ac, H3K9me2, H3K9me3, or nonspecific IgG. Immunocomplexes were assayed by PCR for Dβ1 or JH4 sequences. Wedges indicate sequential 1/4 dilutions of each sample.

Our biochemical analyses of G9a-deficient B cells showed that global levels of H3K9me2 were significantly decreased when compared with control cells (Fig. 1⇑B). However, it remained possible that specific regions within the genome, including TCR loci, retain normal levels of H3K9me2, perhaps via the function of a redundant HMT. To address this possibility, we performed ChIP experiment to probe for modifications on chromatin isolated from pro-B (B220+/Rag2−/−) or a mixture of bone marrow pro- and pre-B cells (B220+/IgM−/Rag2−/−). Deletion of G9a has no effect on levels of H3K9me3 or acetylated H3K9 (H3K9ac) within the DβJβ cluster of these precursor B cells (Fig. 4⇑C). In sharp contrast, H3K9me2 is largely absent from chromatin associated with both the TCRβ and Ig regions in precursor cells from G9a-deficient mice. Together, these results indicate that H3K9me2 is dispensable for tissue-specific repression of recombinase accessibility at Ig and TCR loci.

Inhibition of Igλ gene assembly in G9a-deficient pre-B cells

In addition to tissue specificity, V(D)J recombination proceeds in a stage-specific manner during lymphocyte development. After IgH gene assembly in pro-B cells, V(D)J recombinase is targeted to the Igκ locus for Vκ→Jκ rearrangement in pre-B cells. Should a pre-B cell fail to make a productive join on either Igκ allele, recombinase is then retargeted to the Igλ locus. Consistent with ordered Ig gene assembly, histone modification patterns at Ig loci change during the pro-B to pre-B cell transition (18, 38).

One consequence of ordered IgL gene assembly is a preponderance of mouse B cells that express Igκ as their L chain (∼90% Igκ, 10% Igλ). In this regard, we noted further skewing of IgL isotypes in G9aΔ/Δ serum before or after immunization (Fig. 3⇑B and data not shown). Upon further examination, we found that G9a-deficient mice possess fewer Igλ+ B cells in their spleens (Figs. 5⇓, A and B). This skewing of IgL usage is not simply due to selection in peripheral lymphoid organs because a similar exaggeration of Igκ:Igλ is observed in G9a-deficient bone marrow. Flow cytometry indicated that IgL isotype exclusion remains intact because Igκ+Igλ+ double-expressing cells are absent in G9aΔ/Δ animals (Fig. 5⇓A).

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

Perturbation of Igλ gene assembly in G9a-deficient B cells. A, Skewed IgL usage in G9a-deficient B cells. FACS of bone marrow or spleen cells from mb1-Cre/G9acnd/Δ and control mice stained for surface expression of Igκ and Igλ light chains. FACS data are representative of eight independent mice of each genotype. B, Graphic representation of FACS data for Igλ:Igκ ratios. C, Schematic of the Igλ locus. Boxes represent coding sequences, triangles depict recombination signal sequences, and arrows indicate the predominant Vλ to Jλ rearrangement events observed in mouse B cells. Vλ1 and Vλ2 are separated from their corresponding Jλ segments by ∼20 and 60 kb, respectively. D, DNA extracts were prepared from pro-B, pre-B, or IgM+ bone marrow compartments of G9acnd/Δ and G9aΔ/Δ mice. DNA was analyzed for relative levels of IgH (VH558→J3), Igκ (all Vκ→Jκ1), and Igλ gene rearrangements. Distinct radiolabeled probes were used for general Vλ→Jλ rearrangements or specific VλJλ products as indicated at the right. The linearity of each assay was confirmed using 1/2 dilutions. DNA from the RAG-deficient pro-B cell 63-12 provides a negative control. Cλ serves as a loading control for total DNA content. E, Germline transcription of Ig gene segments. Total mRNA was prepared from pro-B cells (B220+ bone marrow on a RAG-deficient background) or a mixture of pro-B and pre-B cells (IgM−/B220+ bone marrow) from G9acnd/Δ or G9aΔ/Δ mice. RNA samples were subjected to RT-PCR assays specific for JH, Jκ, or individual Vλ and Jλ transcripts as indicated at the left. cDNA from the RAG-deficient pro-T cell line P5424 was included as a negative control and assay linearity was confirmed using serial 1/2 dilutions. F, ChIP assays for H3K9 modifications of IgL loci in G9a-deficient precursor B cells. Chromatin from control and G9a-deficient pro- or pre-B cells was immunoprecipitated with Abs specific for H3K9ac, H3K9me2, H3K9me3, or nonspecific IgG. Immunocomplexes were assayed by PCR for Vλ1, Jλ1, or Jκ sequences. Wedges indicate sequential 1/4 dilutions of each sample.

To test whether redistribution of IgL usage results from perturbations in gene assembly, we measured levels of Vκ→Jκ and Vλ→Jλ joins in purified pro-B, pre-B, and mature B cells from G9a-deficient and control bone marrow. To confirm sorting purities, we measured levels of VH→DHJH and Vκ→Jκ rearrangements in each cell fraction (Fig. 5⇑D). As expected, VH→DHJH rearrangements are readily detected in pro- and pre-B cells from both genotypes, whereas Vκ→Jκ recombinations are restricted to pre-B cells. These data indicate that stage-specific restrictions on Igκ are maintained in the absence of G9a. Thus, premature activation of Igκ does not explain the paucity of Igλ-producing cells in mutant mice. In contrast, Vλ→Jλ rearrangement is consistently reduced ∼3-fold in G9a-deficient pre-B cells (Fig. 5⇑D).

To extend these findings, we examined the effects of G9a deficiency on recombination of specific VλJλ gene segments. The mouse Igλ locus consists of two cassettes with the first encoding a single Vλ gene segment, Vλ1, which rearranges to Jλ1 or Jλ3 (Fig. 5⇑C). A second cassette contains two V and two J segments (Vλ2, Vλx, Jλ2, and Jλ4). The predominant rearrangement in this cassette is Vλ2→Jλ2 because Vλx rarely rearranges and Jλ4 lacks a consensus recombination signal sequence (28). To determine the specificity of Vλ→Jλ rearrangement defects in G9aΔ/Δ mice, we performed PCR assays that distinguish VλJλ joins in each cassette (Vλ1→Jλ1 or Vλ2→Jλ2). As shown in Fig. 5⇑D, Vλ1→Jλ1 and Vλ2→Jλ2 joins are both reduced ∼3-fold in G9aΔ/Δ pre-B cells. These data indicate that G9a potentiates assembly of the entire Igλ locus during B cell development.

The recombination potential of a given gene segment correlates with its germline transcription (39, 40), indicating that shared cis-acting elements regulate chromatin accessibility to transcriptional and recombinational machinery. To investigate accessibility mechanisms at Igλ, we performed assays for germline transcription in pro-B cells isolated from Rag2−/− animals or a mixture of pro-B and pre-B cells (B220+IgM−) from Rag2+/+ mice. These assays revealed a consistent reduction in steady-state levels of germline Vλ1 and Vλ2 transcripts in precursors from G9a-deficient animals (Fig. 5⇑E). In contrast, germline transcripts of Jλ, JH, and Jκ segments are unaffected by the loss of G9a. These data suggest that reduced Igλ usage results from a Vλ-specific defect in chromatin accessibility, which inhibits Vλ→Jλ recombination.

To extend these findings, we performed ChIP analyses on the same cell populations. Consistent with immunoblot analyses of global methylation, H3K9me2 levels are significantly decreased at all IgL loci in G9a-deficient cells (Fig. 5⇑F). Loss of this histone mark alone does not impair V(D)J recombination because similar decreases in H3K9me2 are observed at IgH and Igκ gene segments, which rearranged at wild-type levels. ChIP analyses also revealed a 2- to 3-fold reduction of H3K9 acetylation in G9aΔ/Δ pre-B cells at both the Vλ1 and Vλ2 segments (Fig. 5⇑F and data not shown). In contrast, H3K9 acetylation of Jλ1, Jλ2, and Jκ segments is comparable in wild-type and G9a-deficient pre-B cells (Fig. 5⇑F and data not shown). We conclude that Igλ gene assembly is inhibited in G9a-deficient pre-B cells due to altered patterns of epigenetic modifications at Vλ segments, leading to decreased chromatin accessibility.

Discussion

Lymphocyte development requires a dynamic regulation of gene expression that relies on changes in chromatin modifications. One modification, H3K9me, represses assembly of Ag receptor genes in lymphocytes and generally inhibits gene expression (19, 20, 41). To determine the role of H3K9me2 in lymphocyte development and function, we used tissue-specific deletion of G9a. Despite significant reductions in global H3K9me2, lymphocyte development and stage-/tissue-specific control of V(D)J recombination is unaffected by the loss of G9a. However, Igλ gene assembly in G9a-deficient pre-B cells is decreased, resulting in reduced surface expression and serum levels of this IgL isotype. These data provide the first evidence that G9a-mediated modification of H3K9 controls Ag receptor gene assembly via either direct or indirect mechanisms.

Our biochemical analyses indicate an 80% reduction in global levels of H3K9me2 upon deletion of G9a in pre-B cells. Thus, similar to ES cells, G9a serves as the major H3K9 dimethyltransferase in B lymphocytes (7). We cannot draw an analogous conclusion regarding T cells due to persistent G9a expression following Cre-mediated deletion. Notwithstanding, residual levels of H3K9me2 in lymphocytes from both mutant animals may result from methylation by a compensatory HMT. In this regard, GLP and G9a form heterodimers to cooperatively dimethylate H3K9 (9). However, our observations that global H3K9me2 is reduced in the absence of G9a would indicate that GLP cannot fully substitute for G9a in developing B cells.

Prior studies have shown that significant loss of H3K9me2 during embryonic development is lethal (7), suggesting an important role for G9a in many cellular processes. Therefore, it was surprising that B cell development proceeded unperturbed upon the concomitant loss of G9a and H3K9me2. These findings can be interpreted in several ways, including: 1) H3K9me2 is dispensable in the B lineage and/or other differentiated cells; 2) B cells require minimal levels of H3K9me2; or 3) H3K9me3, which is unaffected by G9a deficiency, compensates for many H3K9me2 functions in differentiated cells. In contrast to developmental processes, we found that BCR-mediated activation of mature B cells is compromised upon loss of G9a. However, general cell division is unaffected by G9a deficiency because mutant B cells respond normally to CD40 cross-linking. More likely, G9a regulates a cohort of genes that are unique to the BCR signaling pathway. Future studies will establish G9a-dependent expression programs that fall under BCR control.

Although G9a-deficient B cells undergo class switching to IgG1 and IgE upon stimulation with LPS and IL-4, these two Ig isotypes are significantly decreased in culture supernatants. However, AID and germline IgG1 expression are unaffected by G9a deficiency, suggesting that attenuated levels of IgG1 and IgE do not result from overt defects in CSR. G9a-deficient B cells exhibit a marked decrease in Blimp-1 and IgJ expression upon LPS + IL-4 stimulation, which correlates with a 2-fold reduction of plasma cells in these cultures. These findings suggest that G9aΔ/Δ B cells fail to fully execute the plasma cell differentiation program under certain stimulatory conditions, which likely accounts for the lower levels of secreted IgG1 and IgE in culture supernatants. Future experiments will define the range of gene expression defects in G9a-deficient B cells and identify relevant G9a target genes that guide terminal differentiation to plasma cells.

H3K9 modifications correlate with activation or repression of V(D)J recombination at Ig and TCR loci. Recombinationally active loci are characterized by H3K9ac, whereas inert loci are hypoacetylated and hypermethylated at this residue (18, 19, 34, 41, 42). Moreover, targeting of G9a to chromosomal substrates suppresses V(D)J recombination (20). Despite these data, we show that tissue-/stage-specific assembly of Ag receptor genes is maintained upon loss of H3K9me2. Our findings suggest that the H3K9me3 mark is sufficient to enforce tissue-specific repression of V(D)J recombination either directly or by impeding acetylation at this residue. Consistent with emerging mechanistic models, these data indicate that changes in a single histone modification are insufficient to initiate gene activation or repression. Instead, activation states are determined by the general pattern of histone modifications at the locus (43). Moreover, essential transcription factors that promote chromatin accessibility or induce H3K9ac at Ag receptor loci may not be activated upon G9a deletion. We conclude that tissue- and/or stage-specificity of V(D)J recombination is controlled at many genetic and epigenetic levels beyond the simple acquisition of H3K9me2.

In contrast to tissue-specific control, we found that loss of G9a perturbed IgL usage at the level of V(D)J recombination. Pre-B cells from mutant mice exhibit a 2- to 3-fold reduction in Vλ→Jλ rearrangement. At face value, our findings are counterintuitive because G9a normally enforces gene repression. However, B cell-specific deletion of a second repressive HMT (Ezh2, H3K27me3) inhibits recombination of VH gene segments (44). In both cases, it remains likely that these HMTs regulate locus recombination via indirect mechanisms. Given the role of G9a in gene repression, we hypothesize that this HMT may normally repress an inhibitor of Igλ locus accessibility. The absence of G9a would lead to enhanced expression of the inhibitor and partial repression of Vλ→Jλ rearrangement. Alternatively, G9a may function by unknown mechanisms to directly activate a transcription factor that promotes Igλ gene assembly (45).

Regardless of the precise mechanism, our data indicate that G9a regulates Igλ specifically by controlling chromatin accessibility at Vλ1 and Vλ2 segments. Loss of G9a significantly reduces germline transcription and H3K9ac at both Vλ segments while sparing these metrics of open chromatin at Jλ segments. These data suggest that a Vλ-specific accessibility control element is regulated by G9a either directly or indirectly. Each Vλ-Jλ cluster contains a single known enhancer (Eλ1–3 and Eλ2–4), an undefined Jλ germline promoter, and promoters situated 5′ of each Vλ segment. However, the ACE function and domain of influence for these transcriptional control elements are unknown (1, 46). We suspect that G9a-mediated control of Igλ is independent of known Eλ enhancers because germline transcription of J segments falls under enhancer control at all other Ig and TCR loci. Instead, we propose that G9a regulates Vλ promoters in the germline Igλ configuration, perhaps by altering the expression of a cognate promoter factor. However, the functional architecture of Vλ promoters is very similar to those driving Vκ and VH expression, suggesting the existence of an unidentified factor specific for Vλ. The advent of G9a-deficient mice such as those reported here will permit a dissection of mechanisms by which this HMT controls chromatin accessibility at Vλ segments and thereby maintains a balance of IgL usage in developing B cells.

Acknowledgments

We thank Danyvid Olivares-Villagomez and Vrajesh Parekh for help with ELISAs and measurement of cell proliferation.

Disclosures

The authors have no financial conflict of interest.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This work was supported by National Institutes of Health Grants P01 HL68744 and CA100905 (to E.M.O.) and F32 AI066691-01A1 (to L.R.T.); Cancer Center Support Grant P30 CA68485, Vanderbilt-Ingram Cancer Center (to E.M.O.); a grant-in-aid from the Ministry of Education, Science, Technology, and Culture of Japan (to Y.S. and M.T.); the 21st Century Center of Excellence Program of the Ministry of Education, Culture, Sports, Science, Technology to the Graduate School of Biostudies (to H.M.); and Deutsche Forschungsgemeinschaft Grant SFB620, Teilprojekte B5 (to M.R.).

  • ↵2 Address correspondence and reprint requests to Dr. Eugene M. Oltz, Department of Microbiology and Immunology, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN 37232. E-mail address: eugene.oltz{at}vanderbilt.edu

  • ↵3 Abbreviations used in this paper: H3K9, histone 3 lysine 9; H3K9me1, me2, and me3, mono-, di-, and trimethylated forms of H3K9; HMT, histone methyltransferase; AID, activation-induced deaminase; CSR, class switch recombination; ChIP, chromatin immunoprecipitation; KLH, keyhole limpet hemocyanin; ES cells, embryonic stem cells; H3K9ac, acetylated H3K9.

  • Received September 4, 2007.
  • Accepted April 16, 2008.
  • Copyright © 2008 by The American Association of Immunologists

References

  1. ↵
    Cobb, R. M., K. J. Oestreich, O. A. Osipovich, E. M. Oltz. 2006. Accessibility control of V(D)J recombination. Adv. Immunol. 91: 45-109.
    OpenUrlCrossRefPubMed
  2. ↵
    Abarrategui, I., M. S. Krangel. 2006. Regulation of T cell receptor-α gene recombination by transcription. Nat. Immunol. 7: 1109-1115.
    OpenUrlCrossRefPubMed
  3. ↵
    Jenuwein, T., C. D. Allis. 2001. Translating the histone code. Science 293: 1074-1080.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Jacobson, R. H., A. G. Ladurner, D. S. King, R. Tjian. 2000. Structure and function of a human Tafii250 double bromodomain module. Science 288: 1422-1425.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Syntichaki, P., I. Topalidou, G. Thireos. 2000. The Gcn5 bromodomain co-ordinates nucleosome remodelling. Nature 404: 414-417.
    OpenUrlCrossRefPubMed
  6. ↵
    Struhl, K.. 1998. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12: 599-606.
    OpenUrlFREE Full Text
  7. ↵
    Tachibana, M., K. Sugimoto, M. Nozaki, J. Ueda, T. Ohta, M. Ohki, M. Fukuda, N. Takeda, H. Niida, H. Kato, Y. Shinkai. 2002. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16: 1779-1791.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Peters, A. H., D. O'Carroll, H. Scherthan, K. Mechtler, S. Sauer, C. Schofer, K. Weipoltshammer, M. Pagani, M. Lachner, A. Kohlmaier, et al 2001. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107: 323-337.
    OpenUrlCrossRefPubMed
  9. ↵
    Tachibana, M., J. Ueda, M. Fukuda, N. Takeda, T. Ohta, H. Iwanari, T. Sakihama, T. Kodama, T. Hamakubo, Y. Shinkai. 2005. Histone methyltransferases G9a and Glp form heteromeric complexes and are both crucial for methylation of euchromatin at H3–K9. Genes Dev. 19: 815-826.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Dodge, J. E., Y. K. Kang, H. Beppu, H. Lei, E. Li. . 2004. Histone H3–K9 methyltransferase eset is essential for early development. Mol. Cell. Biol. 24: 2478-2486.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Tachibana, M., K. Sugimoto, T. Fukushima, Y. Shinkai. 2001. SET domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J. Biol. Chem. 276: 25309-25317.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Wang, H., W. An, R. Cao, L. Xia, H. Erdjument-Bromage, B. Chatton, P. Tempst, R. G. Roeder, Y. Zhang. 2003. Mam facilitates conversion by eset of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol. Cell 12: 475-487.
    OpenUrlCrossRefPubMed
  13. ↵
    Kim, K. C., L. Geng, S. Huang. 2003. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 63: 7619-7623.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Jung, D., F. W. Alt. 2004. Unraveling V(D)J recombination: insights into gene regulation. Cell 116: 299-311.
    OpenUrlCrossRefPubMed
  15. ↵
    Schlissel, M. S.. 2003. Regulating antigen-receptor gene assembly. Nat. Rev. Immunol. 3: 890-899.
    OpenUrlCrossRefPubMed
  16. ↵
    Sen, R., E. Oltz. 2006. Genetic and epigenetic regulation of Igh gene assembly. Curr. Opin. Immunol. 18: 237-242.
    OpenUrlCrossRefPubMed
  17. ↵
    Stanhope-Baker, P., K. M. Hudson, A. L. Shaffer, A. Constantinescu, M. S. Schlissel. 1996. Cell type-specific chromatin structure determines the targeting of V(D)J recombinase activity in vitro. Cell 85: 887-897.
    OpenUrlCrossRefPubMed
  18. ↵
    Johnson, K., D. L. Pflugh, D. Yu, D. G. Hesslein, K. I. Lin, A. L. Bothwell, A. Thomas-Tikhonenko, D. G. Schatz, K. Calame. 2004. B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5. Nat. Immunol. 5: 853-861.
    OpenUrlCrossRefPubMed
  19. ↵
    Morshead, K. B., D. N. Ciccone, S. D. Taverna, C. D. Allis, M. A. Oettinger. 2003. Antigen receptor loci poised for V(D)J rearrangement are broadly associated with Brg1 and flanked by peaks of histone H3 dimethylated at lysine 4. Proc. Natl. Acad. Sci. USA 100: 11577-11582.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Osipovich, O., R. Milley, A. Meade, M. Tachibana, Y. Shinkai, M. S. Krangel, E. M. Oltz. 2004. Targeted inhibition of V(D)J recombination by a histone methyltransferase. Nat. Immunol. 5: 309-316.
    OpenUrlCrossRefPubMed
  21. ↵
    Hobeika, E., S. Thiemann, B. Storch, H. Jumaa, P. J. Nielsen, R. Pelanda, M. Reth. 2006. Testing gene function early in the B cell lineage in mb1-cre mice. Proc. Natl. Acad. Sci. USA 103: 13789-13794.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Lee, P. P., D. R. Fitzpatrick, C. Beard, H. K. Jessup, S. Lehar, K. W. Makar, M. Perez-Melgosa, M. T. Sweetser, M. S. Schlissel, S. Nguyen, et al 2001. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15: 763-774.
    OpenUrlCrossRefPubMed
  23. ↵
    Tachibana, M., M. Nozaki, N. Takeda, Y. Shinkai. 2007. Functional dynamics of H3k9 methylation during meiotic prophase progression. EMBO J. 26: 3346-3359.
    OpenUrlCrossRefPubMed
  24. ↵
    Schlissel, M. S., L. M. Corcoran, D. Baltimore. 1991. Virus-transformed Pre-B cells show ordered activation but not inactivation of immunoglobulin gene rearrangement and transcription. J. Exp. Med. 173: 711-720.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Levin, S. D., S. J. Anderson, K. A. Forbush, R. M. Perlmutter. 1993. A dominant-negative transgene defines a role for P56lck in thymopoiesis. EMBO J. 12: 1671-1680.
    OpenUrlPubMed
  26. ↵
    Goldman, J. P., D. M. Spencer, D. H. Raulet. 1993. Ordered rearrangement of variable region genes of the T cell receptor γ locus correlates with transcription of the unrearranged genes. J. Exp. Med. 177: 729-739.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Capone, M., R. D. Hockett, Jr, A. Zlotnik. 1998. Kinetics of T cell receptor β, γ, and δ rearrangements during adult thymic development: T cell receptor rearrangements are present in Cd44+Cd25+ pro-T thymocytes. Proc. Natl. Acad. Sci. USA 95: 12522-12527.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Bendall, H. H., M. L. Sikes, E. M. Oltz. 2001. Transcription factor Nf-κB regulates Ig λ light chain gene rearrangement. J. Immunol. 167: 264-269.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Whitehurst, C. E., S. Chattopadhyay, J. Chen. 1999. Control of V(D)J recombinational accessibility of the Dβ1 gene segment at the Tcr β locus by a germline promoter. Immunity 10: 313-322.
    OpenUrlCrossRefPubMed
  30. ↵
    Afshar, R., S. Pierce, D. J. Bolland, A. Corcoran, E. M. Oltz. 2006. Regulation of Igh gene assembly: role of the intronic enhancer and 5′dq52 region in targeting Dhjh recombination. J. Immunol. 176: 2439-2447.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    O'Brien, D. P., E. M. Oltz, B. G. Van Ness. 1997. Coordinate transcription and V(D)J recombination of the κ immunoglobulin light-chain locus: Nf-κb-dependent and -independent pathways of activation. Mol. Cell. Biol. 17: 3477-3487.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Klein, U., S. Casola, G. Cattoretti, Q. Shen, M. Lia, T. Mo, T. Ludwig, K. Rajewsky, R. Dalla-Favera. 2006. Transcription factor Irf4 controls plasma cell differentiation and class-switch recombination. Nat. Immunol. 7: 773-782.
    OpenUrlCrossRefPubMed
  33. ↵
    Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (Aid), a potential RNA editing enzyme. Cell 102: 553-563.
    OpenUrlCrossRefPubMed
  34. ↵
    Oestreich, K. J., R. M. Cobb, S. Pierce, J. Chen, P. Ferrier, E. M. Oltz. 2006. Regulation of Tcrβ gene assembly by a promoter/enhancer holocomplex. Immunity 24: 381-391.
    OpenUrlCrossRefPubMed
  35. ↵
    Naim, J. O., M. Satoh, N. A. Buehner, K. M. Ippolito, H. Yoshida, D. Nusz, L. Kurtelawicz, S. F. Cramer, W. H. Reeves. 2000. Induction of hyperγglobulinemia and macrophage activation by silicone gels and oils in female A.SW mice. Clin. Diag. Lab. Immunol. 7: 366-370.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Shaffer, A. L., K. I. Lin, T. C. Kuo, X. Yu, E. M. Hurt, A. Rosenwald, J. M. Giltnane, L. Yang, H. Zhao, K. Calame, L. M. Staudt. 2002. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17: 51-62.
    OpenUrlCrossRefPubMed
  37. ↵
    Gyory, I., J. Wu, G. Fejer, E. Seto, K. L. Wright. 2004. Prdi-Bf1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat. Immunol. 5: 299-308.
    OpenUrlCrossRefPubMed
  38. ↵
    Goldmit, M., Y. Ji, J. Skok, E. Roldan, S. Jung, H. Cedar, Y. Bergman. 2005. Epigenetic ontogeny of the Igk locus during B cell development. Nat. Immunol. 6: 198-203.
    OpenUrlCrossRefPubMed
  39. ↵
    Van Ness, B. G., M. Weigert, C. Coleclough, E. L. Mather, D. E. Kelley, R. P. Perry. 1981. Transcription of the unrearranged mouse Cκ locus: sequence of the initiation region and comparison of activity with a rearranged Vκ-Cκ gene. Cell 27: 593-602.
    OpenUrlCrossRefPubMed
  40. ↵
    Yancopoulos, G. D., F. W. Alt. 1985. Developmentally controlled and tissue-specific expression of unrearranged Vh gene segments. Cell 40: 271-281.
    OpenUrlCrossRefPubMed
  41. ↵
    McMurry, M. T., M. S. Krangel. 2000. A Role for histone acetylation in the developmental regulation of Vdj recombination. Science 287: 495-498.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Chowdhury, D., R. Sen. 2003. Transient Il-7/Il-7r signaling provides a mechanism for feedback inhibition of immunoglobulin heavy chain gene rearrangements. Immunity 18: 229-241.
    OpenUrlCrossRefPubMed
  43. ↵
    Berger, S. L.. 2007. The complex language of chromatin regulation during transcription. Nature 447: 407-412.
    OpenUrlCrossRefPubMed
  44. ↵
    Su, I. H., A. Basavaraj, A. N. Krutchinsky, O. Hobert, A. Ullrich, B. T. Chait, A. Tarakhovsky. 2003. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4: 124-131.
    OpenUrlCrossRefPubMed
  45. ↵
    Vakoc, C. R., S. A. Mandat, B. A. Olenchock, G. A. Blobel. 2005. Histone H3 lysine 9 methylation and HP1γ are associated with transcription elongation through mammalian chromatin. Mol. Cell 19: 381-391.
    OpenUrlCrossRefPubMed
  46. ↵
    Lauster, R., C. A. Reynaud, I. L. Martensson, A. Peter, D. Bucchini, J. Jami, J. C. Weill. 1993. Promoter, enhancer and silencer elements regulate rearrangement of an immunoglobulin transgene. EMBO J. 12: 4615-4623.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Immunology: 181 (1)
The Journal of Immunology
Vol. 181, Issue 1
1 Jul 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Functional Analysis of Histone Methyltransferase G9a in B and T Lymphocytes
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Functional Analysis of Histone Methyltransferase G9a in B and T Lymphocytes
Lance R. Thomas, Hiroki Miyashita, Robin Milley Cobb, Steven Pierce, Makoto Tachibana, Elias Hobeika, Michael Reth, Yoichi Shinkai, Eugene M. Oltz
The Journal of Immunology July 1, 2008, 181 (1) 485-493; DOI: 10.4049/jimmunol.181.1.485

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Functional Analysis of Histone Methyltransferase G9a in B and T Lymphocytes
Lance R. Thomas, Hiroki Miyashita, Robin Milley Cobb, Steven Pierce, Makoto Tachibana, Elias Hobeika, Michael Reth, Yoichi Shinkai, Eugene M. Oltz
The Journal of Immunology July 1, 2008, 181 (1) 485-493; DOI: 10.4049/jimmunol.181.1.485
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Efficient Identification of Tembusu Virus CTL Epitopes in Inbred HBW/B4 Ducks Using a Novel MHC Class I–Restricted Epitope Screening Scheme
  • Poor-Quality Vβ Recombination Signal Sequences and the DNA Damage Response ATM Kinase Collaborate to Establish TCRβ Gene Repertoire and Allelic Exclusion
  • Multifaceted Activities of Seven Nanobodies against Complement C4b
Show more MOLECULAR AND STRUCTURAL IMMUNOLOGY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606